BIONET Therapeutics Corp. (TPEX:7808)
Taiwan flag Taiwan · Delayed Price · Currency is TWD
30.80
-1.30 (-4.05%)
At close: Aug 28, 2026

BIONET Therapeutics Financials Overview

Millions TWD. Fiscal year is Jan - Dec.

Revenue & Profits

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Revenue
196.63154.4881.325.37-
Revenue Growth
27.28%89.96%1414.60%--
Gross Profit
99.161.652.021.8-
Operating Income
-101.67-116.45-99.36-39.26-12.53
Net Income
-84.09-97.43-86.26-37.34-12.52
Earnings Per Share
-1.20-1.39-1.50-2.47-11.43
EPS Growth
-----

Cash & Debt

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Cash & Investments
1,0321,0601,215524.3253.97
Total Debt
23.9510.9---
Net Cash (Debt)
1,0081,0491,215524.3253.97
Net Cash Growth
-3.95%-13.63%131.67%871.44%-
Net Cash Per Share
14.3814.9921.1534.7449.29

Cash Flow & CapEx

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Operating Cash Flow
-38.46-57.48-124.39-34.16-3.47
Capital Expenditures
-52.33-81.19-46.56-12.1-
Free Cash Flow
-90.79-138.68-170.95-46.26-3.47
Free Cash Flow Growth
-----

Margins

Fiscal YearTTMFY 2025FY 2024FY 2023FY 2022
Period EndingJun '26 Dec '25 Dec '24 Dec '23 Dec '22
Gross Margin
50.40%39.91%2.48%33.49%-
Operating Margin
-51.71%-75.38%-122.19%-731.20%-
Pretax Margin
-42.77%-63.07%-106.07%-695.44%-
Profit Margin
-42.77%-63.07%-106.07%-695.44%-
FCF Margin
-46.17%-89.77%-210.22%-861.52%-

Valuation

Fiscal YearCurrentFY 2025FY 2024FY 2023FY 2022
Period EndingAug '26 Dec '25 Dec '24 Dec '23 Dec '22
PS Ratio
11.5225.4739.99--